Ars Technica

New Glenn Catastrophe Aftermath: What's Next for the Space Industry? | Ars Live

Ars Technica — Mon, 6 Jul 2026 16:18:49 +0000

Caleb Henry, Director of Research
Quilty Space

and

Anthony Colangelo, Host
Main Engine Cut Off Podcast

with
Eric Berger, Senior Space Editor
Ars Technica

Is the Artificial Intelligence Bubble About to Pop? | Ars Live

Ars Technica — Thu, 16 Oct 2025 19:52:45 +0000

Ed Zitron
Host, Better Offline Podcast
CEO, EZPR
with
Benj Edwards
Senior Al Reporter
Ars Technica

Tariff Advocacy and Tech: The Semiconductor Scramble | Ars Live

Ars Technica — Mon, 15 Sep 2025 20:49:16 +0000

Edward Brzytwa, Vice President of International Trade
Consumer Technology Association
with
Ashley Belanger, Senior Policy Reporter
Ars Technica

The Heat is On: Climate Science in a Rapidly Changing World | Ars Live

Ars Technica — Fri, 11 Jul 2025 01:30:27 +0000

Zeke Hausfather, Climate Research Lead, Stripe Research Scientist, Berkeley Earth
with
John Timmer, Senior Science Editor, Ars Technica

Red Planet Promises: Is NASA really going to Mars? | Ars Live

Ars Technica — Tue, 10 Jun 2025 16:27:07 +0000

Joey Roulette, Space Reporter Reuters and
Christian Davenport, Staff Writer The Washington Post
with
Eric Berger, Senior Space Editor Ars Technica

Ars Live: Bing Chat—Our First Encounter With Manipulative AI

Ars Technica — Mon, 2 Dec 2024 19:44:34 +0000

In February 2023, Microsoft launched Bing Chat, a tempermental chatbot that gave the world a preview of an unhinged version of OpenAI’s GPT-4 prior to its official release. Its “emotional” nature (including use of emojis) set off alarm bells in the AI alignment community, and the bot tusseled with journalists. With AI researcher Simon Willison, Benj will explore the impact and fallout of the 2023 fiasco.

Ars Live: The rise of GLP-1 drugs: Insights and Unknowns

Ars Technica — Wed, 30 Oct 2024 14:54:22 +0000

Ars Technica Senior Health Reporter Dr. Beth Mole is joined by Dr. Daniel J Drucker, MD, FRCPC from the Lunenfeld Tanenbaum Research Institute for a discussion on the implications, insights, and unknowns around the proliferation and rapid adoption of GLP-1 drugs.